[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"masld-metabolic-dysfunction-associated-steatotic-liver-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:masld-metabolic-dysfunction-associated-steatotic-liver-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,47,75,99,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100622011","efficacy-of-12-week-daytime-restricted-eating-on-hepatic-steatosis-of-obesity-100622011",false,"NCT07378072","Efficacy of 12-week Daytime Restricted Eating on Hepatic Steatosis of Obesity","Efficacy of 12-week Daytime Restricted Eating on Hepatic Steatosis of Obesity: Randomized, Open-label, Parallel Group, Controlled Superiority Trial _ CHRONOSTEATOSIS","CHRONOSTEATOSI","Inclusion Criteria:\n\n* Body mass index (BMI) between 30.0 and 49.9 kg\u002Fm2\n* Age between 18 and 65 years (limits included)\n* Sedentary (light-intensity physical activity less than 1 hour per week) or moderately active (moderate exercise 1 to 2 hours per week). Self-declared criteria.\n* Weight stable for at least 3 months prior to the beginning of the study (gain or loss \\\u003C4 kg). Self-declared criteria.\n* Able to give written informed consent\n* Self-reported eating interval \\> 12 hours per day\n* Subject who owns a smartphone with access to the internet, and agrees to use it in the study\n* Affiliation with French social security system or beneficiary from such system\n* Fibroscan® Controlled Attenuation Parameter (CAP) \\> 300 dB\u002Fms\n* Hepatitis B and C serologies negative (or showing past-infection or protective immunization)\n\nExclusion Criteria:\n\n* Alcohol intake \\> 20 g\u002Fday\n* Night-shift workers or rotating shift workers\n* Smoking\n* Patient with diabetes if HbA1c not at target (\\\u003C7%) and\u002For using a non-authorized medication)\n* Chronic liver disease other than MASLD\n* Severe hepatic disease (cirrhosis, hepatocellular carcinoma)\n* Severe cardiac disease (Chronic heart failure classified as being in New York Heart Association (NYHA) Class III or IV)\n* Severe Kidney disease with CKD-EPI\\\u003C30 mL\u002Fmin\u002F1,73m2\n* Initiation of hormonal treatment during the study period\n* Medications affecting weight or energy balance\n* Magnetic Resonance Imaging (MRI) not possible due to patient's anthropometric characteristics. Any of the following:\n\n  * abdominal and\u002For thoracic circumference with arms greater than 200 cm\n  * Sagittal diameter (or abdominal height, i.e. the distance between the dorsum and the apex of the abdomen, which was measured in the supine position at the midpoint between the iliac crest and the last rib) over 70 cm\n  * body weight over 160 kg\n* MRI not possible due to the following (an MRI safety screening form will have to be filled for inclusion): presence of a pacemaker or cardiac defibrillator or cardiovascular catheter or neurostimulator or an implantable electronic pump for automated drug injection or an electronically-controlled implantable chamber. Ocular metallic foreign bodies\n* History of severe eating disorders: Binge Eating Disorder, Bulimia Nervosa; Night eating syndrome\n* Minors\n* Adults under guardianship, trusteeship or under safeguard of justice\n* Other clinical trial participation that could interfere with the study\n* Pregnant women or women trying to be pregnant\n* Nursing mothers\n* Any treatment triggering hepatic steatosis","ALL","18 Years","65 Years",{"count":21,"type":22},72,"ESTIMATED","INTERVENTIONAL",[25],"NA","The objective of this study is to demonstrate that an \\\u003C or equal to 8-hour time-restricted eating (i.e., fasting for at least 16 hours every day), not focusing on reducing caloric intake, reduces intra-hepatic fat in patients with obesity and Metabolic dysfunction-Associated Steatotic liver Disease (MASLD).",[28],"MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)",[30,31,32,33],"Time-restricted eating","Obesity","MASLD","circadian rhythms","RECRUITING","2026-06-24",{"date":37,"type":38},"2026-06-29","ACTUAL",{"date":40,"type":38},"2026-06-17",{"date":42,"type":22},"2029-06",{"name":44,"class":45},"Nantes University Hospital","OTHER",9,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100642733","unmask-unveiling-the-pathobiology-of-metabolic-dysfunction-associated-steatotic-liver-disease-for-the-discovery-of-novel-therapeutics-and-biomarkers-100642733","NCT07652151","UNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers","UNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers - Study Protocol Version 2.0","UNMASK","Inclusion Criteria:\n\n* Metabolic disarrangements following ATPIII criteria (i.e. comorbidities such as Type 2 diabetes, central obesity, BMI≥\\>25 kg\u002Fm2, hypertension, dyslipidaemia.\n* Written informed consent\n* No dietetical counsellor\u002Fweight loss higher than 10% within the prior 6 months\n* Age over 18 years old\n* Liver stiffness measurement by Fibroscan ≥ 8, CAP ≥ 248 db\u002Fm and MRI PDFF ≥ 5%. ,\n\nExclusion Criteria:\n\n* Significant alcohol intake (≥30 g\u002Fday in men and ≥20 g\u002Fday in women)\n* Other causes of liver disease (evidence of viral or autoimmune hepatitis, HIV, drug-induced fatty liver or other metabolic liver diseases)\n* Use of recreational drugs\n* Decompensated acute or chronic liver disease\n* Cirrhosis or transplant waitlist\n* Pregnancy or parenteral nutrition\n* No nutritional interventions, medications for weight loss or weight loss higher than 5% within the last year\n* Presence of other comorbidities that would impact lifestyle intervention (i. e. prosthesis)\n* Absence of a personal smartphone with a compatible operating system capable of supporting the Amazfit Bip 6 accelerometer app's functionalities: Android 7.0 or iOS 14.0, or later.",{"count":56,"type":22},450,[25],"Overall design: The study will include one intervention based on Mediterranean diet plus structured lifestyle intervention (150 min\u002Fweek of moderate-intensity or 75 min\u002Fweek of high-intensity exercise) for a total of 16 weeks. Following a screening period of up to 12 months, eligible participants will be included in a single cohort.\n\nStudy details include:\n\n* Study duration will be up to 36 months including the screening period.\n* Intervention will be up to 16 weeks.\n* Visit frequency will be every 4 weeks for the interventional period and every 12 weeks during follow-up.",[28],[61,31,62,63,64],"Fibrosis","Personalised Medicine","Patient Phenotyping","Lifestyle intervention","2026-06-18",{"date":67,"type":38},"2026-06-23",{"date":69,"type":38},"2026-01-20",{"date":71,"type":22},"2027-02",{"name":73,"class":45},"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla",3,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":4},"100643433","phase-2-combination-of-cxd-and-restrictive-ketogenic-diet-against-masld-100643433","NCT07639866","Combination of CXD and Restrictive Ketogenic Diet Against MASLD","Clinical Trial Study on the Combination of CXD and Restrictive Ketogenic Diet in Treating MASLD","Inclusion Criteria:\n\n* Age 18-50 years, regardless of gender\n* Meet the diagnostic criteria for MASLD\n* Meet the diagnostic criteria for dampness-heat accumulation syndrome in Traditional Chinese Medicine\n* Liver controlled attenuation parameter (CAP) ≥238 dB\u002Fm\n* Body mass index (BMI) ≥23 kg\u002Fm²\n* Possess adequate cognitive and comprehension abilities to understand the study content, its potential risks, and benefits;\n* Voluntarily participate in this study and personally sign the informed consent form\n\nExclusion Criteria:\n\n* Concurrent presence of other liver diseases that may lead to hepatic steatosis, specifically including drug-induced liver injury, alcoholic liver disease, autoimmune liver disease, viral hepatitis, and Wilson's disease\n* Concurrent severe dysfunction of major organs such as the heart, kidneys, or lungs, e.g., severe cardiac insufficiency (NYHA class III or higher), renal failure (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m²), or acute exacerbation of chronic obstructive pulmonary disease\n* Subjects currently receiving treatment for MASLD\n* Concurrent presence of other severe systemic diseases, such as malignant tumors or active systemic lupus erythematosus\n* Known hypersensitivity or intolerance to any component of the study drug\n* Pregnant women, lactating women, or women of childbearing age who refuse effective contraceptive measures during the trial\n* Participation in other clinical trials within the past 3 months\n* Other circumstances deemed by the investigator unsuitable for participation in this study, such as severe mental disorders affecting compliance with the study","50 Years",{"count":84,"type":22},135,[86],"PHASE2","This study employed a single-center, randomized, investigator-blind, three-group parallel, stepwise controlled clinical trial. A total of 135 subjects were randomly assigned to receive either a low-carbohydrate diet intervention, a restrictive ketogenic diet intervention, or a decoction preparation of the Tucha Lipid-Reducing Formula combined with a restrictive ketogenic diet. The trial duration consisted of 8 weeks of treatment followed by 8 weeks of follow-up. During the trial, participants adhered to dietary calorie control and moderate exercise as instructed in health education, self-reported their height, weight, waist-to-hip ratio, and other general parameters, and had weekly blood ketone level monitoring. Liver ultrasound, fasting blood glucose, lipid profiles, blood ketones, liver function tests, serum creatinine, urea nitrogen levels, and scores on the Traditional Chinese Medicine Syndrome Scale were measured before treatment initiation and at the end of the 8-week treatment period.",[28],"NOT_YET_RECRUITING","2026-06-06",{"date":92,"type":38},"2026-06-10",{"date":94,"type":22},"2026-06-01",{"date":96,"type":22},"2027-02-01",{"name":98,"class":45},"Shanghai Municipal Hospital of Traditional Chinese Medicine",{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":107,"enrollmentInfo":108,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":111,"conditions":112,"keywords":114,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":124,"leadSponsor":126,"locationsCount":128},"100643746","temporal-eating-patterns-and-metabolic-health-100643746","NCT07630636","Temporal Eating Patterns and Metabolic Health","TIME-MET","Inclusion Criteria:\n\nGeneral (applied to all participants)\n\n* Willing and able to give informed consent for participation in the study and perform study assessments\n* Access to a smartphone or computer to complete digital questionnaires and dietary logs.\n\nMASLD Cohort\n\n* Age 18-80\n* Confirmed self-reported MASLD diagnosis, irrespective of disease stage (cases)\n* Control group: Absence of confirmed MASLD diagnosis\n\nEarly Motherhood Cohort\n\n* Age 18-50\n* Women in early motherhood, defined as up to 12 months of their first successful childbirth delivery at enrolment\n* Control group: Women who have never given birth\n\nExclusion Criteria:\n\nAdult participants may not enter the study if ANY of the following apply:\n\n* Self-reported active disease involving major organ dysfunction (except from Type 2 Diabetes Mellitus and Cardiovascular Disease for MASLD cohort)\n* Current smoking, heavy alcohol consumption (AUDIT score greater than 8 will be classified as heavy alcohol consumption), or recreational drug use\n* Current use of appetite-suppressant, appetite-stimulants, or weight-modifying pharmacotherapy (e.g., GLP-1 agonists, antidepressants, GIP agonists)\n* Recent unintentional rapid weight loss greater than 5% of body weight within the past 2 months, not attributable to recent pregnancy or intentional postpartum weight loss.\n* Current shift workers, defined as individuals working regular evening, night, rotating, or irregular schedules that disrupt standard sleep-wake cycles.\n* Currently pregnant or \\>1 year women after childbirth\n* Participants who cannot consent for themselves.",true,"80 Years",{"count":109,"type":22},400,"OBSERVATIONAL","Obesity and its related health problem, like fatty liver disease and type 2 diabetes, are major health problems worldwide and can lead to serious illness and reduced quality of life. Most advice focuses on eating fewer calories and increasing physical activity, but new research suggests that when we eat may also matter. Late meals can disrupt blood sugar control, how the body processes fat, and hormone balance. However, it is not fully understand how meal timing affects people who may be more at-risk. For example new mothers face disrupted sleep, which can lead to eating later in the day. People with fatty liver disease may have eating patterns that unintentionally worsen their condition.\n\nTo explore this, the study will include the following groups;\n\n1. First-time mothers in early motherhood, and women who do not have children.\n2. People with fatty liver disease along with people of similar age, sex, and weight who do not have the condition.\n\nThe aim of the study is to compare meal timing habits between these groups. All participants will complete a 3-day diet diary and a questionnaire about eating habits, sleep, lifestyle, and daily routines. Some participants may opt to complete an optional body composition check using a mobile app. A smaller subset of volunteers will take part in additional assessment, including a fasting blood sample, basic measurements (such as height, weight, and waist size), a body scan to measure fat and muscle. They will also wear a small device to track their blood sugar and another to monitor sleep and activity for 14 days. This study will increase the current understanding on how eating patterns and daily routines differ in these groups, and may help improve future advice on healthy lifestyles.",[28,113],"Early Motherhood",[115,32,113,116,117,118,119],"temporal eating patterns","Metabolic dysfunction-Associated Steatotic Liver Disease","cross-sectional","metabolic health","chrononutrition","2026-06-05",{"date":122,"type":38},"2026-06-08",{"date":94,"type":22},{"date":125,"type":22},"2029-06-01",{"name":127,"class":45},"Maria Chondronikola",1,{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":136,"targetDuration":4,"studyType":110,"phases":4,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":142,"lastUpdatePostDateStruct":143,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":128},"100632830","accurate-point-of-care-liver-disease-diagnostics-phase-2-100632830","NCT07518784","Accurate Point of Care Liver Disease Diagnostics (Phase 2)","Accurate Point of Care Liver Disease Diagnostics","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Known or clinically suspected MASLD\n* BMI greater than 27 kg\u002Fm\\^2 and less than 45 kg\u002Fm\\^2 at the time of referral\n* Ability to lie on LiverScope® device table for about 60 minutes\n* Ability to hold breath repeatedly for about 20 seconds during MR and LiverScope® exams\n* Willing and able to undergo all study procedures\n\nExclusion Criteria:\n\n* UCSD study personnel or Livivos study personne\n* Contraindications to MR\n* Potential participant states that she knows that she is pregnant, thinks she may be pregnant, or states that she is trying to become pregnant.\n* Known chronic liver disease other than MASLD",{"count":137,"type":22},26,"This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in which we are testing a new technology to evaluate the liver (LiverScope®). We will compare LiverScope® to other methods to evaluate the liver, including advanced conventional liver MR exams. MR exams are common exams used to monitor MASLD (also known as NAFLD). Conventional MR scanners use magnetic fields and radio waves to make pictures of the liver. LiverScope® is a small, portable MR-based device that uses similar, but simplified technology, and can be used on top of an exam table in an outpatient setting. LiverScope® currently is not approved for clinical use.\n\nIn this second phase of the study, we took what we learned in the first phase to optimize the LiverScope® device and are now testing to see how LiverScope® measurements compare to MR after these optimizations.\n\nStudy participants will be asked to complete a one-time visit which includes:\n\n* LiverScope exam\n* MR exam\n* FibroScan exam (optional)\n* Blood draw\n* Completion of study questionnaires",[32,28,140,141],"NAFLD","NAFLD (Nonalcoholic Fatty Liver Disease)","2026-04-01",{"date":144,"type":38},"2026-04-09",{"date":146,"type":22},"2026-04-08",{"date":148,"type":22},"2026-06-30",{"name":150,"class":45},"University of California, San Diego"]